Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Single Arm, Multicenter Phase II Study Investigating the Efficacy and Safety of a Novel Therapeutic Scheme in Patients With Unresectable CholAngiocarcinoma: RadioEmbolization in Combination With CisGem and Durvalumab (MEDI4736)

NCT06375915 is registered in ClinicalTrials.gov with Francesco De Cobelli as lead sponsor.

NCT NCT06375915
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06375915 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Single Arm, Multicenter Phase II Study Investigating the Efficacy and Safety of a Novel Therapeutic Scheme in Patients With Unresectable CholAngiocarcinoma: RadioEmbolization in Combination With CisGem and Durvalumab (MEDI4736)
Lead sponsor
Francesco De Cobelli
Phase
Phase 2
Overall status
Recruiting
Start date
April 30, 2024
Completion date
May 31, 2027
Enrollment
33 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

intrahepatic cholangiocarcinoma